GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone needs almost every day. These stocks are able to sustain any economic ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

Also among the top 10 countries by portfolio sales are France, Hungary, Italy, Portugal, Serbia and Switzerland, further enhancing Stada's position as a truly pan-European consumer healthcare player.

GSK thinks its RSV vaccine can be a £3 billion product at its peak ... also confirmed that the long-anticipated spin-off of the consumer health division into a joint venture with Pfizer will ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...